References
- Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007;100:309–27
- Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 2000;12:174–9
- Cote RH. Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. Int J Impotence Res 2004;16:S28–33
- Bella AJ, Deyoung LX, Al-Numi M, Brock GB. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 2007;52:990–1005
- Yoo J, Thai K-M, Kim D-K, et al. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors. Bioorg Med Chem Lett 2007;17:4271–4
- Xia G, Li J, Peng A, et al. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives. Bioorg Med Chem Lett 2005;15:2790–4
- Mojzych M, Rykowski A. One-step synthesis and regioselective alkylation of substituted 1H-pyrazolo[4,3-e][l,2,4]triazine. Polish J Chem 2003;77:1797–804
- Mojzych M, Karczmarzyk Z, Wysocki W, et al. New approaches to the synthesis of sildenafil analogues and their enzyme inhibitory activity. Bioorg Med Chem 2015. [Epub ahead of print]. doi:10.1016/j.bmc.2015.02.026
- Rykowski A, Makosza M. Reaction of 1,2,4-triazines with nitronate anions, direct nucleophilic acylation of 1,2,4-triazines. Tetrahedron Lett 1984;25:4795–7
- Rykowski A, Lipinska A. A concise route to a key intermediate in the total synthesis of Sempervirens. Synth Commun 1996;26:4409–14
- Rykowski A, Mojzych M, Karczmarzyk Z. A new synthesis of pyrazolo[4,3-e][1,2,4]triazines via acid promoted ring closure of the phenylhydrazones of 5-acyl-1,2,4-triazines. Heterocycles 2000;53:2175–85
- Mojzych M, Rykowski A. Transformations of phenylhydrazones of 5-acyl-1,2,4-triazines to pyrazolo[4,3-e][1,2,4]triazines or 4-cyanopyrazole. J Heterocycl Chem 2007;44:1003–7
- Alphonse F-A, Suzenet F, Keromnes A, et al. Palladium-catalyzed 3-thiomethyltriazine-boronic acid cross coupling: easy access to 3-substituted-1,2,4-triazines. Synlett 2002;3:447–50
- Noguera MA, Ivorra MD, Lugnier C, D'Ocon P. Role of cyclic nucleotide phosphodiesterase isoenzymes in contractile responses of denuded rat aorta related to various Ca2+ sources. Naunyn Schmiedebergs Arch Pharmacol 2001;363:612–19
- Mojzych M, Dolashki A, Voelter W. Synthesis of pyrazolo[4,3-e][1,2,4]triazine sulfonamides, novel Sildenafil analogues with tyrosinase inhibitory activity. Bioorg Med Chem 2014;22:6616–24
- Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Therap 2006;109:366–98
- Salom JB, Burguete MC, Pérez-Asensio FJ, et al. Relaxant effect of sildenafil in the rabbit basilar artery. Vascul Pharmacol 2006;44:10–16
- Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488–520
- Lo YC, Tsou HH, Lin RJ, et al. Endothelium-dependent and -independent vasorelaxation by a theophylline derivative MCPT: roles of cyclic nucleotides, potassium channel opening and phosphodiesterase inhibition. Life Sci 2005;76:931–44
- Wu BN, Chen IC, Lin RJ, et al. Aortic smooth muscle relaxants KMUP-3 and KMUP-4, two nitrophenylpiperazine derivatives of xanthine, display cGMP-enhancing activity: roles of endothelium, phosphodiesterase, and K+ channel. J Cardiovasc Pharmacol 2005;46:600–8